WO1994006498A1 - Inhalation device - Google Patents
Inhalation device Download PDFInfo
- Publication number
- WO1994006498A1 WO1994006498A1 PCT/GB1993/002013 GB9302013W WO9406498A1 WO 1994006498 A1 WO1994006498 A1 WO 1994006498A1 GB 9302013 W GB9302013 W GB 9302013W WO 9406498 A1 WO9406498 A1 WO 9406498A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- capsule
- medicament
- inhalation device
- air inlet
- movement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/14—Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws
Definitions
- This invention relates to inhalation devices and in particular to devices for the inhalation of powdered medicament contained in capsules.
- powdered medicament is often supplied in capsules which are loaded into a dispensing device wherein the medicament is released from the capsule then inhaled by the patient.
- GB 1122284 discloses one such device for the inhalation of powdered medicament from a capsule, a preferred embodiment of this device is sold o under the name SPINHALERTM.
- This device has the disadvantage that it must be dismantled for insertion of a capsule prior to inhalation and again to remove the empty capsule after inhalation. Dismantling the device can prove very difficult especially for those with impaired hand movement such as the elderly.
- a medicament inhalation device including a housing defining a through-going pathway provided at one end with an air inlet, and at the other end with a mouthpiece; a drive member rotatably mounted in the housing on a shaft which is coaxial with the longitudinal axi o of the housing, the drive member having, on a portion adjacent to the air inlet, mounting means adapted to engage a medicament capsule, and the drive member being so mounted on the shaft that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member; characterised in that the air inlet is adapted to act as a capsule port through which a 5 capsule can be inserted into the mounting means.
- the device according to the invention preferably includes release means to permit removal of a capsule from the mounting means through the air inlet. -.
- Drive members suitable for use in the device according to the invention 0 include propellers having two or more rotor vanes or blades symmetrically disposed about a central axis or hub, such that impingement of an air stream on the rotor vanes or blades causes rotation of the propeller about the axis or hub.
- the drive member preferably includes a sleeve-like bearing for mounting over the shaft of the device.
- the drive member may be freely mounted on the shaft, however, we prefer the drive member to be retained on the shaft by retaining means
- the retaining means may comprise a circumferential ridge formed on the interior wall of the sleeve-like bearing which is received by a circumferential recess formed on the shaft or vice versa.
- the retaining means prevents the drive member falling of the shaft if the device needs to be dismantled, e.g. for cleaning.
- the vibrational component of the movement of the drive member is essential for release of medicament from the capsule and to obtain constant and reproducible results from the inhalation device.
- Vibrational movement of the drive member may be effected by controlling the dimensions of said member as described in GB 1122284 and GB 1301856 (Fisons pic) the disclosures of which are incorporated herein by reference.
- the device according to the invention preferably includes piercing means for piercing a capsule held in the mounting means.
- Suitable piercing mechanisms will b apparent to those skilled in the art and include e.g. pins or blades.
- the piercing means preferably takes the form of one or more, e.g. two, spring biassed pins.
- Piercing of the capsule may be effected by a cam surface moving over the spring biassed pins, the reciprocal movement of the cam surface allowing the pins to withdraw from the capsule under their spring bias.
- cam surfaces these are preferably provided on the inside of a sleeve slidably mounted on the housing of the device.
- the device may be used for dispensing medicament contained i pre-pierced capsules, i.e. capsules the walls of which are provided with one or more apertures during manufacture; in this case it is not necessary for the device to includ piercing means.
- the air inlet of the device must be large enough to enable it to function as capsule port for the insertion of a medicament capsule into the mounting means.
- the air inlet preferably comprises a circular aperture having a diameter slightly larger than the diameter of a capsule to be inserted into the mounting means.
- the device may be provided with additional air inlets, for example, positioned radially around the capsule port air inlet.
- the housing of the device may act to guide a capsule inserted through the air inlet into the mounting means, this may be achieved by providing a constriction in the housing between the air inlet and the mounting means. This constriction may .. also act to restrict the air stream which flows through the pathway upon inhalation b a patient at the mouthpiece, thus increasing the velocity of air past the capsule and aiding in the release of medicament therefrom.
- the mounting means preferably includes resilient jaws adapted engage a medicament capsule.
- the drive member includes rotor vanes these are preferably integrally moulded with the resilient jaws of the mounting means.
- the device according to the invention preferably includes release means and mounting means including resilient jaws, wherein movement of the release means from a first position to a second position disengages the capsule from the mounting means. Movement of the release means from a first position to a second position may either move the jaws from an engaged to a disengaged position, or transport the capsule from an engaged to a disengaged position.
- the release means When the drive member includes rotor vanes integrally moulded with the resilient jaws then movement of the release means from a first (rest) position to a second (release) position preferably urges the rotor vanes away from the air inlet thereby causing jaws to move from an engaged to a disengaged position.
- the release means transports the capsule from an engaged to a disengaged position, the release means preferably includes an ejection arm which is adapted to urge the capsule out of the mounting means and through the air inlet. In a first (rest) position the ejection arm will be retracted from the mounting means an upon movement to a second (release) position will slide up inside the mounting means thereby ejecting the capsule. Movement of the ejection arm may be effected by an expulsion collar slidably mounted on the drive member.
- the device according to the invention includes release means movement of the release means from a first to a second position is preferably effected by a sleeve slidably mounted on the housing.
- the sleeve preferably performs the dual function of moving the release means and actuating piercing means. Therefore, in a preferred embodiment of the device, movement of the sleeve from a rest position in a direction parallel to the longitudinal axis of housing actuates piercing means for piercing a capsule held in the mounting means; and movement of the sleeve from the rest position in the opposite direction moves the release means from a first position to a second position.
- the device comprises release means this is preferably biased into a - first position, i.e a rest position in which a capsule can be inserted into, and engaged by, the mounting means.
- the device may, if desired, be fitted with a non-return valve so that air may only be inhaled and not blown through the device by the patient.
- the device may be constructed of any suitable material, preferably of a synthetic thermoplastic resin, e.g. high density polyethylene, acrylonitrile butadiene styrene (ABS), or DELRINTM; in which case it can be made by an injection moulding technique.
- a synthetic thermoplastic resin e.g. high density polyethylene, acrylonitrile butadiene styrene (ABS), or DELRINTM; in which case it can be made by an injection moulding technique.
- the capsules for use with the device according to the invention are preferably cylindrical, they may be made from any material which can be pierced, e.g. gelatin.
- the device may be used for dispensing any powdered medicament which is conventionally administered by inhalation to the lung or nose.
- medicaments include drugs for use in the prophylactic or remedial treatment of reversible obstructive airways disease.
- Specific medicaments which may be mentioned include, for example, sodium cromoglycate and nedocromil sodium; inhaled steroids such as beclomethasone dipropionate, tipredane, and fluticasone; anticholinergic agents such as ipratropium bromide; bronchodilators, e.g. salmeterol, salbutamol, reproterol, terbutaline, albuterol and fenoterol; and salts thereof.
- bronchodilators e.g. salmeterol, salbutamol, reproterol, terbutaline, albuterol and fenoterol
- salts thereof e.g. salmeterol, salbutamol, reproterol, terbutaline,
- Devices according to the invention have advantages over known inhalation devices in that the procedures for insertion of the medicament capsule into the device, and for removal of the empty capsule from the device after inhalation, are considerably simplified. Furthermore, since the device does not need to be dismantled for insertion/removal of the capsule, the patient is less likely to inadvertently injure themselves on the piercing means; and the propeller-like member, if freely mounted on the shaft, cannot fall off the shaft during the insertion/removal procedure.
- Figure 1 is a perspective view of a device according to the invention.
- Figure 2 is a longitudinal section of the device of Figure 1 in the rest position
- Figure 3 is a section along the line III-III of Figure 2;
- Figure 4 is a longitudinal section of the device of Figure 1 in the release position;
- Figure 5 is a perspective view of an alternative device according to the invention.
- Figure 6 is a longitudinal section of the device of Figure 5 in the rest position
- Figure 7 is a section along the line VII- VII of Figure 6;
- Figure 8 is a longitudinal section of the device of Figure 5 in the release position
- a medicament inhalation device comprises a generally cylindrical housing (1) describing a through-going pathway.
- the housing (1) is provided at one end with a mouthpiece portion (2), optionally having a removable mouthpiece cover (not shown), and provided at the other end with an air inlet (3).
- a shaft (4) is rigidly mounted coaxially with the housing (1), the end of shaft (4) adjacent to the mouthpiece (2) end of housing (1) being supported by cross members (5).
- Propeller (6) having a sleeve-like bearing (7) is mounted on shaft (4).
- Shaft (4) is provided with a circumferential recess (8) which receives a circumferential ridge (9) formed on the interior wall of bearing (7) such that dissociation of the shaft (4) and the propeller (6) is prevented.
- Propeller (6) is provided with a capsule mounting cup (10) comprising four resilient segments (11), shown best in Figure 3, which is adapted of engage a capsule (12) containing powdered medicament to be inhaled.
- Propeller (6) is also provided with four rotor vanes (13) integrally moulded with segments (11), which cause the propeller (6) to rotate on shaft (4) when air is drawn through the pathway, as during inhalation. ..
- Two stainless steel piercing needles (14), spring biased into the rest position s shown in Figures 2, are provided on housing (1).
- One end of each needle (14) being secured to the housing (1), the other end being curved inwards such that they point towards a capsule (12) engaged by segments (11) of cup (10).
- a sleeve (15) is slidably mounted on housing (1).
- cam surfaces may be integrally moulded with the sleeve, however, for ease of manufacture they may be moulded separately and located in the sleeve during assembly of the device).
- sleeve (15) turns inwards on itself thus s defining the walls of the air inlet (3).
- Sleeve (15) extends further within housing (1) to form a circular release collar (17) which is located between the air inlet (3) and rotor vanes (13).
- the collar (17) is adapted to apply downwards pressure onto rotor vanes (13) thus urging them away from the air inlet (3), thereby causing the segments (11) of cup 0 (10) to splay outwards.
- the air inlet end of sleeve (15) urges needles (14) slightly inwards against their bias, this effect may be further enhanced by the provision of cam surfaces within the sleeve.
- a capsule (12) containing powdered medicament to be inhaled is inserted through air inlet (3) and engaged by the segments (11) of cup (10).
- Sleeve 5 (15) is then moved in the direction of arrow A in Figure 2 causing the cam surfaces
- the patient then inhales through mouthpiece (2), thereby drawing air 0 through the pathway in the direction of arrow B in Figure 2.
- the flow of air through the pathway causes the propeller (6) to rotate about shaft (4) and also to vibrate.
- the medicament is thereby dispensed from capsule (12) through the apertures formed by needles (14), entrained in the air flow and inhaled by the patient.
- the device is held with the air inlet (3) pointing downwards and sleeve (15) is moved over housing (1) in the direction of arrow C in Figure 4 (this may be achieved by pushing the sleeve and .. mouthpiece towards each other).
- release collar (17) presses onto rotor vanes (13), s the pressure on rotor vanes (13) causing segments (11) to splay outwards from the base of cup (10) thus disengaging the empty capsule (12) which falls out of the housing (1) through the air inlet, as shown in Figure 4.
- the sleeve (15) then returns to its rest position under the bias of needles (14) and the inhalation device is once more ready for use.
- the release means includes a cylindrical ejection collar (18) slidably mounted around the housing (1).
- the collar (18) is provided with projecting lugs (19) which cooperate with corresponding lugs (20) provided on the inside of sleeve (15).
- Ejection collar (18) is also provided with two transverse arms (21) which project into housing (1). s Arms (21) abut against the base of a secondary ejection collar (22) slidably mounted around sleeve-like bearing (7). The secondary ejection collar (22) has two arms (23) running parallel to bearing (7) which extend through the base of mounting cup (10). Ejection collar (18) is biased into the rest position shown in Figure 6 by spring (24). In use, a capsule (12) containing medicament to be inhaled is inserted o through air inlet (3) and engaged by the segments (11) of cup (10). Sleeve (15) is then moved in the direction of arrow D in Figure 6 causing the cam surfaces (16) to engage needles (14) and pierce capsule (12).
- sleeve (15) is moved in the direction of arrow E in Figure 8, lugs (19, 20) slide the ejection collar (18) over housing (1) against the bias of spring 5 (24).
- the arms (21) of the ejection collar (18) push the secondary ejection collar (22) up the bearing (4) and arms (23) are raised into cup (10) thereby ejecting the empty capsule (12) out of the housing (1) through the air inlet (23).
- the sleeve (15) then returns to its rest position under the bias of spring (24) and the inhalation device is once more ready for use.
Abstract
A medicament inhalation device including a housing (1) defining a throughgoing pathway provided at one end with an air inlet (3), and at the other end with a mouthpiece (2); a drive member (6) rotatably mounted in the housing (1) on a shaft (4) which is coaxial with the longitudinal axis of the housing (1), the drive member (6) having, on a portion adjacent to the air inlet (3), mounting means (10) adapted to engage a medicament capsule (12), and the drive member (6) being so mounted on the shaft (4) that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member (6); characterised in that the air inlet (3) is adapted to act as a capsule port through which a capsule (12) can be inserted into the mounting means (10).
Description
INHALATION DEVICE
This invention relates to inhalation devices and in particular to devices for the inhalation of powdered medicament contained in capsules.
The administration of inhalation medicaments in dry powder form is well 5 known. Powdered medicament is often supplied in capsules which are loaded into a dispensing device wherein the medicament is released from the capsule then inhaled by the patient.
GB 1122284 (Fisons pic) discloses one such device for the inhalation of powdered medicament from a capsule, a preferred embodiment of this device is sold o under the name SPINHALER™. This device has the disadvantage that it must be dismantled for insertion of a capsule prior to inhalation and again to remove the empty capsule after inhalation. Dismantling the device can prove very difficult especially for those with impaired hand movement such as the elderly.
We have now devised an improved inhalation device which overcomes or s substantially mitigates the disadvantages of the device described above.
According to the present invention, there is provided a medicament inhalation device including a housing defining a through-going pathway provided at one end with an air inlet, and at the other end with a mouthpiece; a drive member rotatably mounted in the housing on a shaft which is coaxial with the longitudinal axi o of the housing, the drive member having, on a portion adjacent to the air inlet, mounting means adapted to engage a medicament capsule, and the drive member being so mounted on the shaft that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member; characterised in that the air inlet is adapted to act as a capsule port through which a 5 capsule can be inserted into the mounting means.
In addition, the device according to the invention preferably includes release means to permit removal of a capsule from the mounting means through the air inlet. -.
Drive members suitable for use in the device according to the invention 0 include propellers having two or more rotor vanes or blades symmetrically disposed about a central axis or hub, such that impingement of an air stream on the rotor vanes or blades causes rotation of the propeller about the axis or hub.
The drive member preferably includes a sleeve-like bearing for mounting over the shaft of the device. The drive member may be freely mounted on the shaft, however, we prefer the drive member to be retained on the shaft by retaining means
The retaining means may comprise a circumferential ridge formed on the interior wall of the sleeve-like bearing which is received by a circumferential recess formed on the shaft or vice versa. The retaining means prevents the drive member falling of the shaft if the device needs to be dismantled, e.g. for cleaning.
The vibrational component of the movement of the drive member is essential for release of medicament from the capsule and to obtain constant and reproducible results from the inhalation device. Vibrational movement of the drive member may be effected by controlling the dimensions of said member as described in GB 1122284 and GB 1301856 (Fisons pic) the disclosures of which are incorporated herein by reference.
The device according to the invention preferably includes piercing means for piercing a capsule held in the mounting means. Suitable piercing mechanisms will b apparent to those skilled in the art and include e.g. pins or blades. The piercing means preferably takes the form of one or more, e.g. two, spring biassed pins.
Piercing of the capsule may be effected by a cam surface moving over the spring biassed pins, the reciprocal movement of the cam surface allowing the pins to withdraw from the capsule under their spring bias. When piercing is effected by means of cam surfaces these are preferably provided on the inside of a sleeve slidably mounted on the housing of the device.
Alternatively the device may be used for dispensing medicament contained i pre-pierced capsules, i.e. capsules the walls of which are provided with one or more apertures during manufacture; in this case it is not necessary for the device to includ piercing means.
The air inlet of the device must be large enough to enable it to function as capsule port for the insertion of a medicament capsule into the mounting means.
The air inlet preferably comprises a circular aperture having a diameter slightly larger than the diameter of a capsule to be inserted into the mounting means. The device may be provided with additional air inlets, for example, positioned radially around the capsule port air inlet.
The housing of the device may act to guide a capsule inserted through the air inlet into the mounting means, this may be achieved by providing a constriction in the housing between the air inlet and the mounting means. This constriction may .. also act to restrict the air stream which flows through the pathway upon inhalation b a patient at the mouthpiece, thus increasing the velocity of air past the capsule and aiding in the release of medicament therefrom.
The mounting means preferably includes resilient jaws adapted engage a medicament capsule. When the drive member includes rotor vanes these are preferably integrally moulded with the resilient jaws of the mounting means. The device according to the invention preferably includes release means and mounting means including resilient jaws, wherein movement of the release means from a first position to a second position disengages the capsule from the mounting means. Movement of the release means from a first position to a second position may either move the jaws from an engaged to a disengaged position, or transport the capsule from an engaged to a disengaged position.
When the drive member includes rotor vanes integrally moulded with the resilient jaws then movement of the release means from a first (rest) position to a second (release) position preferably urges the rotor vanes away from the air inlet thereby causing jaws to move from an engaged to a disengaged position. When the release means transports the capsule from an engaged to a disengaged position, the release means preferably includes an ejection arm which is adapted to urge the capsule out of the mounting means and through the air inlet. In a first (rest) position the ejection arm will be retracted from the mounting means an upon movement to a second (release) position will slide up inside the mounting means thereby ejecting the capsule. Movement of the ejection arm may be effected by an expulsion collar slidably mounted on the drive member.
When the device according to the invention includes release means movement of the release means from a first to a second position is preferably effected by a sleeve slidably mounted on the housing. The sleeve preferably performs the dual function of moving the release means and actuating piercing means. Therefore, in a preferred embodiment of the device, movement of the sleeve from a rest position in a direction parallel to the longitudinal axis of housing actuates piercing means for piercing a capsule held in the mounting means; and movement of
the sleeve from the rest position in the opposite direction moves the release means from a first position to a second position.
When the device comprises release means this is preferably biased into a - first position, i.e a rest position in which a capsule can be inserted into, and engaged by, the mounting means.
The device may, if desired, be fitted with a non-return valve so that air may only be inhaled and not blown through the device by the patient.
The device may be constructed of any suitable material, preferably of a synthetic thermoplastic resin, e.g. high density polyethylene, acrylonitrile butadiene styrene (ABS), or DELRIN™; in which case it can be made by an injection moulding technique.
Although the device according to the invention has thus far been described for use in oral inhalation of medicaments, it is also suitable for the administration of nasal medicaments by inhalation. The necessary adaptation for this mode of administration will be readily apparent to those skilled in the art.
The capsules for use with the device according to the invention are preferably cylindrical, they may be made from any material which can be pierced, e.g. gelatin.
The device may be used for dispensing any powdered medicament which is conventionally administered by inhalation to the lung or nose. Such medicaments include drugs for use in the prophylactic or remedial treatment of reversible obstructive airways disease. Specific medicaments which may be mentioned include, for example, sodium cromoglycate and nedocromil sodium; inhaled steroids such as beclomethasone dipropionate, tipredane, and fluticasone; anticholinergic agents such as ipratropium bromide; bronchodilators, e.g. salmeterol, salbutamol, reproterol, terbutaline, albuterol and fenoterol; and salts thereof. If desired a mixture of medicaments, for example a mixture of sodium cromoglycate and a bronchodilator, such as reproterol or a salt thereof, may be used.
Devices according to the invention have advantages over known inhalation devices in that the procedures for insertion of the medicament capsule into the device, and for removal of the empty capsule from the device after inhalation, are considerably simplified. Furthermore, since the device does not need to be dismantled for insertion/removal of the capsule, the patient is less likely to
inadvertently injure themselves on the piercing means; and the propeller-like member, if freely mounted on the shaft, cannot fall off the shaft during the insertion/removal procedure.
The invention will now be described, by way of example only, with reference to the accompanying drawings, in which:
Figure 1 is a perspective view of a device according to the invention;
Figure 2 is a longitudinal section of the device of Figure 1 in the rest position;
Figure 3 is a section along the line III-III of Figure 2; Figure 4 is a longitudinal section of the device of Figure 1 in the release position;
Figure 5 is a perspective view of an alternative device according to the invention;
Figure 6 is a longitudinal section of the device of Figure 5 in the rest position;
Figure 7 is a section along the line VII- VII of Figure 6; and
Figure 8 is a longitudinal section of the device of Figure 5 in the release position;
In the Figures corresponding features of the alternative devices are given the same reference numeral.
Referring firstly to Figures 1 to 4: a medicament inhalation device comprises a generally cylindrical housing (1) describing a through-going pathway. The housing (1) is provided at one end with a mouthpiece portion (2), optionally having a removable mouthpiece cover (not shown), and provided at the other end with an air inlet (3).
A shaft (4) is rigidly mounted coaxially with the housing (1), the end of shaft (4) adjacent to the mouthpiece (2) end of housing (1) being supported by cross members (5). Propeller (6) having a sleeve-like bearing (7) is mounted on shaft (4). Shaft (4) is provided with a circumferential recess (8) which receives a circumferential ridge (9) formed on the interior wall of bearing (7) such that dissociation of the shaft (4) and the propeller (6) is prevented. Propeller (6) is provided with a capsule mounting cup (10) comprising four resilient segments (11), shown best in Figure 3, which is adapted of engage a capsule (12) containing
powdered medicament to be inhaled. Propeller (6) is also provided with four rotor vanes (13) integrally moulded with segments (11), which cause the propeller (6) to rotate on shaft (4) when air is drawn through the pathway, as during inhalation. .. Two stainless steel piercing needles (14), spring biased into the rest position s shown in Figures 2, are provided on housing (1). One end of each needle (14) being secured to the housing (1), the other end being curved inwards such that they point towards a capsule (12) engaged by segments (11) of cup (10). A sleeve (15) is slidably mounted on housing (1). Cam surfaces (16) located on the inside of sleeve
(15) are adapted to engage piercing needles (14) thus pushing them into a capsule o (12) engaged by segments (11) of cup (10) when the sleeve (15) is slid in the direction of arrow A in Figure 2. (The cam surfaces may be integrally moulded with the sleeve, however, for ease of manufacture they may be moulded separately and located in the sleeve during assembly of the device).
At the air inlet (3) end of housing (1) sleeve (15) turns inwards on itself thus s defining the walls of the air inlet (3). Sleeve (15) extends further within housing (1) to form a circular release collar (17) which is located between the air inlet (3) and rotor vanes (13). When sleeve (15) is moved in the direction of arrow C in Figure 4 the collar (17) is adapted to apply downwards pressure onto rotor vanes (13) thus urging them away from the air inlet (3), thereby causing the segments (11) of cup 0 (10) to splay outwards. In this position the air inlet end of sleeve (15) urges needles (14) slightly inwards against their bias, this effect may be further enhanced by the provision of cam surfaces within the sleeve.
In use, a capsule (12) containing powdered medicament to be inhaled is inserted through air inlet (3) and engaged by the segments (11) of cup (10). Sleeve 5 (15) is then moved in the direction of arrow A in Figure 2 causing the cam surfaces
(16) to engage needles (14) and pierce capsule (12). Reciprocal movement of the sleeve (15) allows needles (14) to withdraw from the pierced capsule (12) under thei spring bias.
The patient then inhales through mouthpiece (2), thereby drawing air 0 through the pathway in the direction of arrow B in Figure 2. The flow of air through the pathway causes the propeller (6) to rotate about shaft (4) and also to vibrate. The medicament is thereby dispensed from capsule (12) through the apertures formed by needles (14), entrained in the air flow and inhaled by the patient.
Once the patient has inhaled the medicament, the device is held with the air inlet (3) pointing downwards and sleeve (15) is moved over housing (1) in the direction of arrow C in Figure 4 (this may be achieved by pushing the sleeve and .. mouthpiece towards each other). Release collar (17) presses onto rotor vanes (13), s the pressure on rotor vanes (13) causing segments (11) to splay outwards from the base of cup (10) thus disengaging the empty capsule (12) which falls out of the housing (1) through the air inlet, as shown in Figure 4. The sleeve (15) then returns to its rest position under the bias of needles (14) and the inhalation device is once more ready for use. o In an alternative embodiment of the device shown in Figures 5 to 8 the release means includes a cylindrical ejection collar (18) slidably mounted around the housing (1). The collar (18) is provided with projecting lugs (19) which cooperate with corresponding lugs (20) provided on the inside of sleeve (15). Ejection collar (18) is also provided with two transverse arms (21) which project into housing (1). s Arms (21) abut against the base of a secondary ejection collar (22) slidably mounted around sleeve-like bearing (7). The secondary ejection collar (22) has two arms (23) running parallel to bearing (7) which extend through the base of mounting cup (10). Ejection collar (18) is biased into the rest position shown in Figure 6 by spring (24). In use, a capsule (12) containing medicament to be inhaled is inserted o through air inlet (3) and engaged by the segments (11) of cup (10). Sleeve (15) is then moved in the direction of arrow D in Figure 6 causing the cam surfaces (16) to engage needles (14) and pierce capsule (12). Once the medicament has been inhaled by the patient, sleeve (15) is moved in the direction of arrow E in Figure 8, lugs (19, 20) slide the ejection collar (18) over housing (1) against the bias of spring 5 (24). The arms (21) of the ejection collar (18) push the secondary ejection collar (22) up the bearing (4) and arms (23) are raised into cup (10) thereby ejecting the empty capsule (12) out of the housing (1) through the air inlet (23). The sleeve (15) then returns to its rest position under the bias of spring (24) and the inhalation device is once more ready for use.
Claims
1. A medicament inhalation device includes a housing (1) defining a through- going pathway provided at one end with an air inlet (3), and at the other end with a mouthpiece (2); a drive member (6) rotatably mounted in the housing (1) on a shaft s (4) which is coaxial with the longitudinal axis of the housing (1), the drive member (6) having, on a portion adjacent to the air inlet (3), mounting means (10) adapted to engage a medicament capsule (12), and the drive member (6) being so mounted on the shaft (4) that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member (6); characterised in that o the air inlet (3) is adapted to act as a capsule port through which a capsule (12) can be inserted into the mounting means (10).
2. A medicament inhalation device according to claim 1, wherein the device includes release means (17) to permit removal of a capsule (12) from the mounting means (10) through the air inlet (3). s
3. A medicament inhalation device according to claim 2, wherein the mounting means (10) includes resilient jaws (11) adapted to engage a medicament capsule (12) and movement of the release means (17) from a first position to a second position disengages the capsule (12) from the mounting means (10).
4. A medicament inhalation device according to claim 3, wherein movement of 0 the release means (17) from a first position to a second position moves the jaws (11) from an engaged to a disengaged position.
5. A medicament inhalation device according to claim 4, wherein the drive member (6) includes rotor vanes (13) integrally moulded with the resilient jaws (11) of the mounting means (10), and movement of the release means (17) from a first to 5 a second position urges the rotor vanes (13) away from the air inlet (3) thereby causing jaws (11) to move from an engaged to a disengaged position.
6. A medicament inhalation device according to claim 3, wherein movement of the release means (17) upon moving from a first to a second position transports the capsule (12) from an engaged to a disengaged position. 0
7. A medicament inhalation device according to claim 6, wherein the release means includes an ejection arm (23) adapted to urge the capsule (12) out of the mounting means (10) and through the air inlet (3).
8. A medicament inhalation device according to any one of the preceding claims, wherein movement of the release means (17) from a first to a second position is effected by a sleeve (15) slidably mounted on the housing (1).
9. A medicament inhalation device according to claim 6, wherein movement of the sleeve (15) from a rest position in a direction parallel to the longitudinal axis of housing (1) actuates piercing means (14) for piercing a capsule (12) held in the mounting means (10); and movement of the sleeve (15) from the rest position in the opposite direction moves the release means (17) from a first to a second position.
10. A medicament inhalation device according to any one of the preceding claims, in which the release means (17) is biased into the first position.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48295/93A AU4829593A (en) | 1992-09-23 | 1993-09-23 | Inhalation device |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9220077.3 | 1992-09-23 | ||
GB929220077A GB9220077D0 (en) | 1992-09-23 | 1992-09-23 | Inhalation device |
GB9220083.1 | 1992-09-23 | ||
GB929220083A GB9220083D0 (en) | 1992-09-23 | 1992-09-23 | Inhalation device |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994006498A1 true WO1994006498A1 (en) | 1994-03-31 |
Family
ID=26301671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/002013 WO1994006498A1 (en) | 1992-09-23 | 1993-09-23 | Inhalation device |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4829593A (en) |
WO (1) | WO1994006498A1 (en) |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0755276A1 (en) * | 1994-04-14 | 1997-01-29 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
EP0796628A2 (en) * | 1996-03-21 | 1997-09-24 | Unisia Jecs Corporation | Inhaler |
WO1998030263A1 (en) | 1997-01-09 | 1998-07-16 | Sepracor, Inc. | Multiple-dose dispenser for dry powder inhalers |
US5947118A (en) * | 1993-06-03 | 1999-09-07 | Boehringer Ingelheim Kg | Capsule holder |
US5996577A (en) * | 1995-08-11 | 1999-12-07 | Unisia Jecs Corporation | Medicine administering apparatus |
US6089228A (en) * | 1994-09-21 | 2000-07-18 | Inhale Therapeutic Systems | Apparatus and methods for dispersing dry powder medicaments |
WO2002024266A1 (en) * | 2000-09-25 | 2002-03-28 | Microdrug Ag | Foil cutter |
WO2004002417A2 (en) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
US6679256B2 (en) | 1999-12-17 | 2004-01-20 | Nektar Therapeutics | Systems and methods for extracting powders from receptacles |
WO2005097175A2 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
US7252087B2 (en) | 2003-11-08 | 2007-08-07 | Boehringer Ingelheim International Gmbh | Powder inhaler |
WO2007118800A1 (en) * | 2006-04-11 | 2007-10-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mouthpiece for an inhaler |
WO2007118858A1 (en) * | 2006-04-15 | 2007-10-25 | Boehringer Ingelheim International Gmbh | Inhaler |
WO2008021237A1 (en) | 2006-08-10 | 2008-02-21 | Arubor Corporation | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
US7456288B2 (en) | 2003-10-28 | 2008-11-25 | Reddy Us Therapeutics, Inc. | Heterocyclic compounds and methods of making and using thereof |
EP2090657A2 (en) | 2000-08-07 | 2009-08-19 | Centocor Ortho Biotech Inc. | Anti-IL-12 antibodies, compositions, methods and uses |
WO2009139733A1 (en) * | 2008-05-16 | 2009-11-19 | Mahmut Bilgic | Dry powder inhalation device |
EP2123675A2 (en) | 2003-09-30 | 2009-11-25 | Centocor Ortho Biotech Inc. | Human EPO mimentic hinge core mimetibodies, compositions, methods and uses |
EP2159230A1 (en) | 2000-08-07 | 2010-03-03 | Centocor Ortho Biotech Inc. | Anti-TNF antibodies, compositions, methods and uses |
WO2010051274A2 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
WO2010111485A1 (en) | 2009-03-25 | 2010-09-30 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US7833531B2 (en) | 2006-12-21 | 2010-11-16 | Centocor, Inc. | Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists |
EP2253646A1 (en) | 2000-08-07 | 2010-11-24 | Centocor Ortho Biotech Inc. | Anti-dual integrin antibody and compositions and conjugates comprising said antibody |
EP2308888A1 (en) | 2001-11-14 | 2011-04-13 | Centocor Ortho Biotech Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
EP2452694A1 (en) | 2005-06-30 | 2012-05-16 | Janssen Biotech, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
WO2012175735A1 (en) | 2011-06-23 | 2012-12-27 | Vib Vzw | A20 inhibitors for the treatment of respiratory viral infections |
EP2548577A1 (en) | 2005-12-29 | 2013-01-23 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
US8481053B2 (en) | 2002-02-13 | 2013-07-09 | Immunology Laboratories, Inc. | Compositions and methods for treating of microbial infections |
WO2014106459A2 (en) | 2013-01-07 | 2014-07-10 | Superlab Far East Limited | A method for treating tumor by using recombinant interferon with changed spatial configuration |
WO2014135224A1 (en) * | 2013-03-08 | 2014-09-12 | Interquim, S.A. | Inhaler |
WO2014144763A2 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan Kettering Cancer Center | High affinity anti-gd2 antibodies |
US8875701B2 (en) | 2006-04-11 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Inhaler |
EP2842968A1 (en) | 2005-04-29 | 2015-03-04 | Janssen Biotech, Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
KR20160116056A (en) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Anti-il-12/il-23 antibodies |
EP3138601A1 (en) * | 2015-09-04 | 2017-03-08 | Victor Esteve | Dry powder inhaler |
WO2018014038A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors and methods for use |
WO2018014039A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
WO2018087699A2 (en) | 2016-11-09 | 2018-05-17 | The Board Of Regents Of The University Of Texas System | Methods and compositions for adaptive immune modulation |
EP3323830A1 (en) | 2010-06-19 | 2018-05-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
WO2018112037A1 (en) | 2016-12-16 | 2018-06-21 | Jia Zhou | Inhibitors of bromodomain-containing protein 4 (brd4) |
WO2018115915A1 (en) * | 2016-12-20 | 2018-06-28 | Emphasys Importadora Exportadora E Distribuidora Ltda. | Dry powder inhaler |
WO2018140026A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
EP1399105B2 (en) † | 2001-06-13 | 2018-09-05 | Boehringer Ingelheim Pharma GmbH & Co.KG | Method for cleaning hard gelatine capsules |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
WO2019126574A1 (en) | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
WO2019215701A1 (en) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Methods of treating depression using il-23 antibodies |
WO2020148651A1 (en) | 2019-01-15 | 2020-07-23 | Janssen Biotech, Inc. | Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
WO2020152544A1 (en) | 2019-01-23 | 2020-07-30 | Janssen Biotech, Inc. | Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis |
WO2020183270A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
WO2020183269A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2020183271A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
WO2020245677A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
WO2020245676A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
US11014982B2 (en) | 2017-02-07 | 2021-05-25 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
US11041020B2 (en) | 2017-01-30 | 2021-06-22 | Janssen Biotech, Inc. | Methods for the treatment of active Psoriatic Arthritis |
WO2021211628A1 (en) | 2020-04-14 | 2021-10-21 | Poseida Therapeutics, Inc. | Compositions and methods for use in the treatment of cancer |
WO2021214588A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating coronavirus infections |
WO2021214587A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating viral infections |
WO2022026943A2 (en) | 2020-07-31 | 2022-02-03 | Pinetree Therapeutics, Inc. | Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections |
US11389433B2 (en) | 2018-06-18 | 2022-07-19 | Board Of Regents, The University Of Texas System | BRD4 inhibitor treatment of IgE-mediated diseases |
WO2023279115A1 (en) | 2021-07-02 | 2023-01-05 | Henry Ford Health System | Compositions comprising endosidin 2 for reducing sars-cov-2 infection |
WO2023281462A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
EP4190817A1 (en) | 2015-03-17 | 2023-06-07 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
EP3986514A4 (en) * | 2019-06-24 | 2023-08-09 | De Motu Cordis Pty Ltd | Automatic dispenser for respiratory delivery device |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH461035A (en) * | 1966-09-17 | 1968-08-15 | Fisons Pharmaceuticals Ltd | Device for oral inhalation of drugs in finely divided form |
GB1268051A (en) * | 1968-06-07 | 1972-03-22 | Fisons Pharmaceuticals Ltd | Inhalation device |
FR2380032A1 (en) * | 1977-02-10 | 1978-09-08 | Allen & Hanburys Ltd | CAPSULE INHALER |
-
1993
- 1993-09-23 AU AU48295/93A patent/AU4829593A/en not_active Abandoned
- 1993-09-23 WO PCT/GB1993/002013 patent/WO1994006498A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH461035A (en) * | 1966-09-17 | 1968-08-15 | Fisons Pharmaceuticals Ltd | Device for oral inhalation of drugs in finely divided form |
GB1268051A (en) * | 1968-06-07 | 1972-03-22 | Fisons Pharmaceuticals Ltd | Inhalation device |
FR2380032A1 (en) * | 1977-02-10 | 1978-09-08 | Allen & Hanburys Ltd | CAPSULE INHALER |
Cited By (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5947118A (en) * | 1993-06-03 | 1999-09-07 | Boehringer Ingelheim Kg | Capsule holder |
EP0755276A4 (en) * | 1994-04-14 | 1998-04-01 | Dura Pharma Inc | Dry powder inhaler |
EP0755276A1 (en) * | 1994-04-14 | 1997-01-29 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US6089228A (en) * | 1994-09-21 | 2000-07-18 | Inhale Therapeutic Systems | Apparatus and methods for dispersing dry powder medicaments |
US5996577A (en) * | 1995-08-11 | 1999-12-07 | Unisia Jecs Corporation | Medicine administering apparatus |
EP0796628A2 (en) * | 1996-03-21 | 1997-09-24 | Unisia Jecs Corporation | Inhaler |
EP0796628A3 (en) * | 1996-03-21 | 1998-05-06 | Unisia Jecs Corporation | Inhaler |
WO1998030263A1 (en) | 1997-01-09 | 1998-07-16 | Sepracor, Inc. | Multiple-dose dispenser for dry powder inhalers |
US5794613A (en) * | 1997-01-09 | 1998-08-18 | Sepracor, Inc. | Multiple-dose dispenser for dry powder inhalers |
US6679256B2 (en) | 1999-12-17 | 2004-01-20 | Nektar Therapeutics | Systems and methods for extracting powders from receptacles |
EP2330129A2 (en) | 2000-08-07 | 2011-06-08 | Centocor Ortho Biotech Inc. | Anti-TNF antibodies, compositions, methods and uses |
EP3118318A1 (en) | 2000-08-07 | 2017-01-18 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, methods and uses |
EP2305817A2 (en) | 2000-08-07 | 2011-04-06 | Centocor Ortho Biotech Inc. | Anti-IL-12 antibodies, compositions, methods and uses |
EP2253646A1 (en) | 2000-08-07 | 2010-11-24 | Centocor Ortho Biotech Inc. | Anti-dual integrin antibody and compositions and conjugates comprising said antibody |
EP3597752A1 (en) | 2000-08-07 | 2020-01-22 | Janssen Biotech, Inc. | Anti-il-12 antibodies, compositions, methods and uses |
EP2090657A2 (en) | 2000-08-07 | 2009-08-19 | Centocor Ortho Biotech Inc. | Anti-IL-12 antibodies, compositions, methods and uses |
EP2159230A1 (en) | 2000-08-07 | 2010-03-03 | Centocor Ortho Biotech Inc. | Anti-TNF antibodies, compositions, methods and uses |
WO2002024266A1 (en) * | 2000-09-25 | 2002-03-28 | Microdrug Ag | Foil cutter |
EP1399105B2 (en) † | 2001-06-13 | 2018-09-05 | Boehringer Ingelheim Pharma GmbH & Co.KG | Method for cleaning hard gelatine capsules |
EP2308888A1 (en) | 2001-11-14 | 2011-04-13 | Centocor Ortho Biotech Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
US9539292B2 (en) | 2002-02-13 | 2017-01-10 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
US9962434B2 (en) | 2002-02-13 | 2018-05-08 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
US8481053B2 (en) | 2002-02-13 | 2013-07-09 | Immunology Laboratories, Inc. | Compositions and methods for treating of microbial infections |
US9241984B2 (en) | 2002-02-13 | 2016-01-26 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
US9511101B2 (en) | 2002-02-13 | 2016-12-06 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
US8518416B2 (en) | 2002-02-13 | 2013-08-27 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
US9072694B2 (en) | 2002-02-13 | 2015-07-07 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
US8920815B2 (en) | 2002-02-13 | 2014-12-30 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
WO2004002417A2 (en) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
EP2123675A2 (en) | 2003-09-30 | 2009-11-25 | Centocor Ortho Biotech Inc. | Human EPO mimentic hinge core mimetibodies, compositions, methods and uses |
US7456288B2 (en) | 2003-10-28 | 2008-11-25 | Reddy Us Therapeutics, Inc. | Heterocyclic compounds and methods of making and using thereof |
US7252087B2 (en) | 2003-11-08 | 2007-08-07 | Boehringer Ingelheim International Gmbh | Powder inhaler |
WO2005097175A2 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
EP2842968A1 (en) | 2005-04-29 | 2015-03-04 | Janssen Biotech, Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
EP2452694A1 (en) | 2005-06-30 | 2012-05-16 | Janssen Biotech, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
EP3501537A1 (en) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
EP3219328A1 (en) | 2005-12-29 | 2017-09-20 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, method and uses |
EP2548577A1 (en) | 2005-12-29 | 2013-01-23 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
EP3760230A1 (en) | 2005-12-29 | 2021-01-06 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
US8875701B2 (en) | 2006-04-11 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Inhaler |
WO2007118800A1 (en) * | 2006-04-11 | 2007-10-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mouthpiece for an inhaler |
US8281784B2 (en) | 2006-04-11 | 2012-10-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mouthpiece for an inhaler |
EP2656867A3 (en) * | 2006-04-11 | 2014-01-22 | Boehringer Ingelheim Pharma GmbH & Co. KG | Mouthpiece for an inhalator |
JP2009533112A (en) * | 2006-04-11 | 2009-09-17 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Inhaler mouthpiece |
JP2009533192A (en) * | 2006-04-15 | 2009-09-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Inhaler |
WO2007118858A1 (en) * | 2006-04-15 | 2007-10-25 | Boehringer Ingelheim International Gmbh | Inhaler |
US8196578B2 (en) | 2006-04-15 | 2012-06-12 | Boehringer Ingelheim International Gmbh | Inhaler |
US11718853B2 (en) | 2006-08-10 | 2023-08-08 | Onspira Therapeutics, Inc. | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
EP3669878A1 (en) | 2006-08-10 | 2020-06-24 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
WO2008021237A1 (en) | 2006-08-10 | 2008-02-21 | Arubor Corporation | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
US7833531B2 (en) | 2006-12-21 | 2010-11-16 | Centocor, Inc. | Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists |
WO2009139733A1 (en) * | 2008-05-16 | 2009-11-19 | Mahmut Bilgic | Dry powder inhalation device |
KR20160116056A (en) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Anti-il-12/il-23 antibodies |
WO2010051274A2 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
EP3128048A1 (en) | 2008-10-31 | 2017-02-08 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
US9186400B2 (en) | 2009-03-25 | 2015-11-17 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
WO2010111485A1 (en) | 2009-03-25 | 2010-09-30 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US9504742B2 (en) | 2009-03-25 | 2016-11-29 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US10722573B2 (en) | 2009-03-25 | 2020-07-28 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
EP4269563A2 (en) | 2010-06-19 | 2023-11-01 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
EP3323830A1 (en) | 2010-06-19 | 2018-05-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
WO2012175735A1 (en) | 2011-06-23 | 2012-12-27 | Vib Vzw | A20 inhibitors for the treatment of respiratory viral infections |
WO2014106459A2 (en) | 2013-01-07 | 2014-07-10 | Superlab Far East Limited | A method for treating tumor by using recombinant interferon with changed spatial configuration |
EP3895725A2 (en) | 2013-01-07 | 2021-10-20 | Superlab Far East Limited | A method for treating tumor by using recombinant interferon with changed spatial configuration |
WO2014135224A1 (en) * | 2013-03-08 | 2014-09-12 | Interquim, S.A. | Inhaler |
WO2014144763A2 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan Kettering Cancer Center | High affinity anti-gd2 antibodies |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
EP4190817A1 (en) | 2015-03-17 | 2023-06-07 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
EP3138601A1 (en) * | 2015-09-04 | 2017-03-08 | Victor Esteve | Dry powder inhaler |
WO2018014038A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors and methods for use |
WO2018014039A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
US11826422B2 (en) | 2016-11-09 | 2023-11-28 | Board Of Regents, The University Of Texas System | Methods and compositions for adaptive immune modulation |
WO2018087699A2 (en) | 2016-11-09 | 2018-05-17 | The Board Of Regents Of The University Of Texas System | Methods and compositions for adaptive immune modulation |
US11117865B2 (en) | 2016-12-16 | 2021-09-14 | Board Of Regents, The University Of Texas System | Inhibitors of bromodomain-containing protein 4 (BRD4) |
WO2018112037A1 (en) | 2016-12-16 | 2018-06-21 | Jia Zhou | Inhibitors of bromodomain-containing protein 4 (brd4) |
WO2018115915A1 (en) * | 2016-12-20 | 2018-06-28 | Emphasys Importadora Exportadora E Distribuidora Ltda. | Dry powder inhaler |
US11517686B2 (en) | 2016-12-20 | 2022-12-06 | Emphasys Importadora Exportadora E Distribuidora Ltda. | Dry powder inhaler |
WO2018140026A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
US11041020B2 (en) | 2017-01-30 | 2021-06-22 | Janssen Biotech, Inc. | Methods for the treatment of active Psoriatic Arthritis |
US11014982B2 (en) | 2017-02-07 | 2021-05-25 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
WO2019126574A1 (en) | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
WO2019215701A1 (en) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Methods of treating depression using il-23 antibodies |
US11389433B2 (en) | 2018-06-18 | 2022-07-19 | Board Of Regents, The University Of Texas System | BRD4 inhibitor treatment of IgE-mediated diseases |
WO2020148651A1 (en) | 2019-01-15 | 2020-07-23 | Janssen Biotech, Inc. | Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
WO2020152544A1 (en) | 2019-01-23 | 2020-07-30 | Janssen Biotech, Inc. | Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis |
WO2020183269A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2020183270A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
WO2020183271A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
WO2020245676A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
WO2020245677A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
EP3986514A4 (en) * | 2019-06-24 | 2023-08-09 | De Motu Cordis Pty Ltd | Automatic dispenser for respiratory delivery device |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
WO2021211628A1 (en) | 2020-04-14 | 2021-10-21 | Poseida Therapeutics, Inc. | Compositions and methods for use in the treatment of cancer |
WO2021214588A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating coronavirus infections |
WO2021214587A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating viral infections |
WO2022026943A2 (en) | 2020-07-31 | 2022-02-03 | Pinetree Therapeutics, Inc. | Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections |
WO2023279115A1 (en) | 2021-07-02 | 2023-01-05 | Henry Ford Health System | Compositions comprising endosidin 2 for reducing sars-cov-2 infection |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023281462A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
Also Published As
Publication number | Publication date |
---|---|
AU4829593A (en) | 1994-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994006498A1 (en) | Inhalation device | |
KR100321814B1 (en) | Dry powder inhaler | |
US5787881A (en) | Inhalation device | |
KR0177265B1 (en) | Dry powder inhaler | |
KR100218816B1 (en) | Powder inhaler | |
RU2393883C1 (en) | Simple inhaler | |
KR100323942B1 (en) | Medicine Inhaler and Inhalation Method | |
RU2332240C2 (en) | Doser cartridge with preliminary measuring of dry inhalator powder | |
US5243970A (en) | Dosing device for administering metered amounts of powdered medicaments to patients | |
JP5651233B2 (en) | Simple capsule-based inhaler | |
FI67026C (en) | ANDNINGSAKTIVERAD ANORDNING FOER ORAL INHALATION AV POWDER FORM CEILINGS | |
US4116195A (en) | Device for dispensing medicaments | |
US9050427B2 (en) | Dry powder inhalers with multi-facet surface deagglomeration chambers and related devices and methods | |
JPH04227269A (en) | Dosing device for powder medicine | |
JPH08509626A (en) | Inhaler | |
WO2007093310A2 (en) | Dry powder inhaler device | |
JPH0147190B2 (en) | ||
CN105916491B (en) | Inhalable medicaments | |
JP2001524363A (en) | Dry powder inhaler | |
JPH06509958A (en) | powder dispenser | |
JPH08103499A (en) | Inhalation type medicine administrator | |
US20130025593A1 (en) | Dry powder inhaler | |
JPH05505738A (en) | drug inhalation device | |
WO2002089875A1 (en) | Powder deaggregation device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |